A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Last updated: July 30, 2025
Sponsor: Bristol-Myers Squibb
Overall Status: Completed

Phase

N/A

Condition

Lymphoproliferative Disorders

Bone Neoplasm

Red Blood Cell Disorders

Treatment

Elotuzumab in combination with pomalidomide and dexamethasone

Elotuzumab in combination with lenalidomide and dexamethasone

Clinical Study ID

NCT06163040
CA204-219
  • Ages > 18
  • All Genders

Study Summary

This observational study aimed to assess the safety of elotuzumab when used in combination with pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma (RRMM) in participants who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The study will also assess the safety of elotuzumab when used in combination with lenalidomide and dexamethasone in RRMM participants who had received one to three prior therapies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Confirmed diagnosis of RRMM

  • Received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor

  • Planning to receive elotuzumab in combination with pomalidomide and dexamethasone atphysician's medical judgement OR

  • Age ≥ 18 years

  • Confirmed diagnosis of RRMM

  • Received one to three prior therapies

  • Planning to receive elotuzumab in combination with lenalidomide and dexamethasone atphysician's medical judgement

Exclusion

Exclusion Criteria:

  • Participants with therapeutic indications for which elotuzumab in combination withpomalidomide/lenalidomide and dexamethasone has not been approved in Taiwan

  • Participants who are contraindicated for treated with elotuzumab in combination withpomalidomide/lenalidomide and dexamethasone (as described in the Taiwan label)

  • Participants who participate in other interventional clinical trials

Study Design

Total Participants: 7
Treatment Group(s): 2
Primary Treatment: Elotuzumab in combination with pomalidomide and dexamethasone
Phase:
Study Start date:
December 22, 2023
Estimated Completion Date:
March 17, 2025

Connect with a study center

  • Chang Gung Memorial Hospital- Chiayi

    Chiayi City, Chiayi 613
    Taiwan

    Site Not Available

  • Local Institution - 0002

    Chiayi City, Chiayi 613
    Taiwan

    Site Not Available

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung, 80756
    Taiwan

    Site Not Available

  • Local Institution - 0003

    Kaohsiung, 80756
    Taiwan

    Site Not Available

  • National Taiwan University Hospital

    Taipei, 100229
    Taiwan

    Site Not Available

  • China Medical University Hospital

    Taoyuan City, 40447
    Taiwan

    Site Not Available

  • Local Institution - 0004

    Taoyuan City, 40447
    Taiwan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.